Inovio Pharmaceuticals Is a Leader in the Race for a COVID-19 Vaccine
Excerpt from the article:
“As SARS-CoV-2, the deadly coronavirus responsible for COVID-19, spread from Wuhan, China, to nearly every country around the globe, dozens of companies rushed to develop a vaccine against the novel virus.
The Coalition for Epidemic Preparedness Innovations (CEPI), a leading global funder of vaccine development, put its vote of confidence in Plymouth Meeting biotech company Inovio Pharmaceuticals. In January, CEPI awarded Inovio an initial $9 million grant to accelerate the company’s DNA medicine platform for vaccine development. By the end of April, CEPI would award the company a total of $17.2 million to boost the large-scale manufacturing of Inovio’s vaccine. The company has also received funding from other organizations including the Bill & Melinda Gates Foundation. Inovio is the first company to prove that DNA medicine, which activates the body’s immune response, can be delivered directly into a patient’s cells using the company’s smart device, known as Cellectra.”
Click the button below to read the article:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?